An analysis of the data from the CABOSUN and METEOR trials has shown that expression of the PD-L1 receptor in tumour cells did not predict outcomes with cabozantinib (Cabometyx) among patients with advanced renal cell carcinoma (RCC). This analysis was presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich over the weekend.

Expression of the PD-L1 receptor in tumour cells is associated with better outcomes for patients with advanced/metastatic RCC treated with the immune checkpoint inhibitors, nivolumab and ipilimumab. PD-L1 may, therefore, be a predictive biomarker for treatment outcomes. The current analysis of the CABOSUN and METEOR data was carried out to determine if PD-L1 tumour expression could be a predictive biomarker for cabozantinib efficacy.

In conclusion, cabozantinib can continue to be used either alone or in combination with an immune checkpoint inhibitor in  patients with and without PD-L1 tumour expression.

Read more in Cancer Therapy Advisor here

Read the ESMO press release here